11 results about "Pantoprazole" patented technology

The invention provides pantoprazole sodium for injection, which is prepared by dissolving 40 parts of pantoprazole sodium, 25 parts of amino-PEG-mannose, 0.5 part of disodium calcium ethylene diamine tetraacetate and water for injection to 1000 parts and freeze-drying, the redissolution time of pantoprazole sodium for injection is short, related substances in the solution are not increased, the content is not obviously reduced, and the pantoprazole sodium for injection is suitable for clinical application. The stability is good in the transportation and storage process, the compatible solution can be stored for a long time during clinical use, clinical use becomes more convenient, and the problems of medication potential safety hazards, side effects and the like brought to patients due to impurity increase, content reduction and the like are also greatly reduced.

The present invention relates to pantoprazole sodium preparations, and relates to a sublingual tablet containing pantoprazole sodium, at least one diluent, at least two flavoring agents, at least one taste masking agent, at least one binder, at least one disintegrant, at least one lubricant, and at least two buffer salts. The preparation contains 20 mg of pantoprazole sodium; the sublingual tablet of pantoprazole sodium in a specific ratio has a quality that meets the requirements of sublingual tablets and has a relatively fast disintegration and dissolution rate. Other advantages of the pharmaceutical preparation of the present invention are simple preparation process, stable product quality, rapid dissolution of the drug, and fast onset of action. The present invention also relates to a preparation method of the pantoprazole sodium sublingual tablet. The sample prepared by this method complies with the relevant regulations of sublingual tablets.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

The invention relates to the technical field of preparation of enteric-coated materials, and discloses a continuous preparation process of enteric-coated pills containing a flow-aiding anti-blocking agent, which comprises the following steps: S1, premixing pill core raw materials according to a prescription, then adding purified water to form a wet material, preparing the wet material into pills, and drying at 50-60 DEG C to obtain pill cores; and S2, coating the pill core obtained in the step S1 by using an isolating layer coating solution, coating by using an enteric layer coating solution after the weight of a coating is increased by 3-6%, finishing coating after the weight of the coating is increased by 8-12%, and screening out oversized or undersized pills to obtain the enteric coated pill containing the flow-aiding anti-blocking agent. According to the invention, a material system is simplified and the production cost is reduced through multi-layer application of an auxiliary material, the whole-process continuous production from pellet core forming to multi-layer coating is realized through structural design and process adaptation, and a technical scheme is provided for preparation of high-difficulty enteric-coated preparations such as pantoprazole sodium preparations sensitive to humidity and heat.

The present invention provides a concentrated, storage stable, liquid composition of pantoprazole or a pharmaceutically acceptable salt thereof. The invention further provides uses for the composition, and packaging containers comprising the composition. In particular, the present invention relates to stable pantoprazole sodium formulations with controlled room temperature as storage condition, in the form of a ready-to-use liquid solution or in the form of a ready-to-dilute formulation, for dilution with infusion solution, processes for their preparation and use.

The present application provides a method for quantitatively analyzing acid-suppressing drugs by a high-performance liquid chromatography-tandem mass spectrometry device, comprising: preparing a sample solution containing the acid-suppressing drug; injecting the sample solution into the high-performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and quantitatively analyzing the acid-suppressing drug using an internal standard method according to the mass chromatogram, wherein the acid-suppressing drug is selected from: esomeprazole, rabeprazole, ilaprazole, lansoprazole, pantoprazole and vonoprazan fumarate; using a mixed mobile phase consisting of mobile phase A and mobile phase B for gradient elution in the high-performance liquid chromatography, wherein mobile phase A is an acetonitrile solution containing formic acid or a water-acetonitrile mixture containing ammonia and ammonium acetate (water: acetonitrile volume ratio: 1:99-10:90); and mobile phase B is selected from an aqueous solution containing ammonium acetate, an aqueous solution containing formic acid and ammonium acetate, an aqueous solution containing ammonia and ammonium acetate, and an aqueous solution containing ammonia and ammonium formate.

The invention relates to the field of effective and economical conversion of nitro or nitroso compounds in to corresponding amines. More it discloses a reduction processes of nitro or nitroso compounds to corresponding amino compounds, which exhibit differential solubility, exemplified & not restricted to the processes discussed for m-aminoacetophenone, the intermediate of Phenylephrine, ethyl3- [[4-(methylamino)-3-aminobenzoyl](pyridin2yl)amino]propanoate the intermediate of Dabigatran, and 2,4-Difluoroaniline the intermediate of Pantoprazole. Even more particularly, the invention relates to a process involving use of minimal quantity of water or quantity of water required only as the source of hydrogen for generation of sufficient reduction potential to perform the chemical reaction. The process offers a. safer, cost competitive and greener alternative to the conventional process of reduction. A key benefit of the invention is that it avoids side product / s & / or impurity / s resulting from usage of large quantity of water especially when other sensitive / reactive groups are present in the molecule.

The present invention provides a concentrated, storage stable, liquid composition of pantoprazole or a pharmaceutically acceptable salt thereof. The invention further provides uses for the composition, and packaging containers comprising the composition. In particular, the present invention relates to stable pantoprazole sodium formulations with controlled room temperature as storage condition, in the form of a ready-to-use liquid solution or in the form of a ready-to-dilute formulation, for dilution with infusion solution, processes for their preparation and use.

This utility model relates to the field of pharmaceutical powder dispensing technology, and discloses a rotary worktable for dispensing pantoprazole sodium powder with quantitative dispensing capability. The worktable includes a worktable with a fixed plate fixedly connected to its rear side. A storage tank is fixedly connected to the upper front end of the fixed plate, and a discharge cylinder is fixedly connected to the bottom of the storage tank. An mounting plate is fixedly connected to the middle of the front end of the fixed plate, and support plates are fixedly connected to both sides of the mounting plate. A sliding groove is formed on one adjacent side of each of the two support plates, and a sliding plate is slidably connected between the two grooves. A quantitative cylinder is passed through and fixedly connected to the bottom of the sliding plate. A flip-top plate is rotatably connected to the bottom of the quantitative cylinder, and a discharge cylinder is fixedly connected to the front end of the mounting plate. In this utility model, a motor, in conjunction with a first gear and a second gear, drives the rotating column and the rotary table to rotate. After the quantitative cylinder completes one discharge cycle, the motor rotates at a preset angle to achieve continuous dispensing.

The invention discloses a preparation method of pantoprazole sodium enteric-coated tablets, and relates to the technical field of pantoprazole sodium enteric-coated tablets, and the preparation method comprises the following preparation steps: step 1, preparing pantoprazole sodium; 2, the raw materials are sieved by a 120-200-mesh sieve and then mixed for 15-25 min, and a pre-mixture is obtained; step 3, taking out the premixture with the mass being 2.5-3.5 times that of the magnesium stearate, mixing the premixture with the magnesium stearate for 3-5 minutes, sieving through a 120-200-mesh sieve, and continuously stirring and mixing for 5-10 minutes; and step 4, tabletting and coating to obtain the pantoprazole sodium enteric-coated tablet. According to the preparation method of the pantoprazole sodium enteric-coated tablet, 2-chloromethyl-3, 4-dimethoxypyridine hydrochloride and 5-difluoromethoxy-2-sulfydryl-1H-benzimidazole are taken as starting materials to synthesize pantoprazole sodium, the total yield of the product is 67.3% on average, the purity of the pantoprazole sodium is 99.95% on average, the purity of the pantoprazole sodium is 99.95% on average, and the purity of the pantoprazole sodium is 99.95% on average. Materials and reagents used in the synthesis process are materials for industrial production, low in price and easy to obtain, the synthesis process is simple to operate, and the synthesized pantoprazole sodium is high in purity and good in stability.

An application of pantoprazole in the preparation of an enhancer for an MSLN-CAR-T cell therapy against brain metastases. Treating with pantoprazole prior to MSLN-CAR-T therapy increases MSLN protein expression, particularly on cell surfaces, reduces MSLN target antigen expression heterogeneity, and improves the homing ability and killing ability of MSLN-CAR-T cells.